A phase Ib/IIa trial to evaluate the CCK2 receptor antagonist Z-360 in combination with gemcitabine in patients with advanced pancreatic cancer.
(2010) European Journal of Cancer — Vol. 46, n° 3, p. 526-533 (2010)
Files
pdfdocument.pdf
Restricted Access - Adobe PDF
- 190.35 KB
Details
- Authors
- Abstract
- To evaluate the combination of the gastrin antagonist Z-360 and gemcitabine for advanced pancreatic cancer.
- Affiliations
Citations
Meyer, T., Caplin, M. E., Palmer, D. H., Valle, J. W., Larvin, M., Waters, J. S., Coxon, F., Borbath, I., Peeters, M., Nagano, E., & Kato, H. (2010). A phase Ib/IIa trial to evaluate the CCK2 receptor antagonist Z-360 in combination with gemcitabine in patients with advanced pancreatic cancer. European Journal of Cancer, 46(3), 526-533. https://doi.org/10.1016/j.ejca.2009.11.004 (Original work published 2010)